Donal P. McLornan

SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor–Naïve Patients With Myelofibrosis

Ruben A. Mesa, Jean‐Jacques Kiladjian, John Catalano et al. · Journal of Clinical Oncology · 2017 · 345 citations · Full text

Hematological Malignancy, Immunohematology, Momelotinib 200 +13

Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells

Nimitha R. Mathew, Francis Baumgartner, Lukas M. Braun et al. · Nature Medicine · 2018 · 283 citations · Full text

Cell Therapy, Flt3-itd-mutant Leukemia Cells, Immunology +7

Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study

Srđan Verstovšek, Aaron T. Gerds, Alessandro M. Vannucchi et al. · The Lancet · 2023 · 164 citations

Hematological Malignancy, Bone Marrow Failure, Momelotinib Versus Danazol +6

Guideline for the investigation and management of eosinophilia

Nauman M. Butt, Jonathan Lambert, Sahra Ali et al. · British Journal of Haematology · 2017 · 162 citations · Full text

Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors

Mohamed Shanavas, Uday Popat, Laura C. Michaelis et al. · Biology of Blood and Marrow Transplantation · 2015 · 142 citations · Full text

Antifibrotic Therapy, Immunology, Pathology +16